Results 111 to 120 of about 32,827 (233)

Tiny carriers, big impact: How Fusobacterium nucleatum extracellular vesicles drive oral diseases and beyond

Interdisciplinary Medicine, EarlyView.
This review explores how Fusobacterium nucleatum extracellular vesicles drive local oral diseases and distal pathologies via sophisticated cross‐compartment cross talk. It highlights the transformative potential of these “tiny carriers” as next‐generation molecular intermediaries for advanced health monitoring and innovative bio‐interventions by ...
Rongyang Ma, Jiahui Huang, Yitong Chen, Haoxuan Wang, Hang Zou, Wanghong Zhao, Zilong Deng   +6 more
wiley   +1 more source

Oxaliplatin in Cisplatin-Resistant Cancer

, 2007
Oxaliplatin is widely regarded as being active in cisplatin-resistant cancer. We undertook a systematic review of the literature to identify, describe and critique the clinical and pre-clinical evidence for the use of oxaliplatin in patients with ...
STORDAL, BRITTA KRISTINA
core  

Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells.

, 2010
Preclinical studies have indicated that there is only partial cross-resistance between cisplatin and oxaliplatin. The molecular background for this is incompletely known. To investigate the differences in resistance, we rendered a colon cancer cell line (
Kjellström, Johan, Ekblad, Lars, Johnsson, Anders   +2 more
core   +2 more sources

Targeting the intratumoral microbiota to overcome cancer immunotherapy resistance

Interdisciplinary Medicine, EarlyView.
This review delineates the mechanisms of intratumoral microbiota in cancer immunotherapy resistance, and offers strategies for microbiota‐targeted precision immunotherapy. Abstract Cancer remains a significant global health threat. The tumor microenvironment (TME) is a sophisticated ecological niche that exerts a pivotal effect on treatment outcomes ...
Bufu Tang, Tong Jiang, Yaling Lin, Wei Zhang, Hongjie Fan, Minjie Yang, Bingzhe Li, Yaozu Liu, Changyu Li, Xuran Jin, Wen Zhang, Zhiping Yan, Qianqian Zhao, Xuefeng Kan, Xudong Qu   +14 more
wiley   +1 more source

The Role of Prostaglandin E2 Signaling in Acquired Oxaliplatin Resistance

, 2017
The platinum-base chemotherapeutic agent, oxaliplatin, is used to treat metastatic colorectal cancer (CRC). Unfortunately, nearly all patients develop acquired resistance to oxaliplatin after long-term use, limiting its therapeutic efficacy.
Huang, Huakang
core  

Abstract 1187: Synthetic lethality screening reveals ATR as responsible for oxaliplatin resistance in colorectal cancer cells

, 2017
Despite the recent advances achieved in the treatment of colon cancer, tumor resistance is a frequent cause of chemotherapy failure. Our work was aimed to determine the molecular mechanisms involved in the resistance to oxaliplatin, an anticancer agent ...
Eve Combes, Maguy Del Rio, Nadia Vie, Céline Gongora, Roderick Beijersbergen, Diego Tosi, Pierre Martineau, Augusto Faria-Andrade   +7 more
core   +1 more source

Synergistic antitumor effects of endostar in combination with oxaliplatin via inhibition of HIF and CXCR4 in the colorectal cell line SW1116.

PLoS ONE, 2012
Combination treatment with endostar, a novel modified endostatin, and cytotoxic chemotherapies showed a survival benefit in Chinese clinical trials. However, the exact mechanism for this synergism remains unclear.
Fengyan Jin, Huifan Ji, Chunshu Jia, Ulf Brockmeier, Dirk M Hermann, Eric Metzen, Yingqiao Zhu, Baorong Chi   +7 more
doaj   +1 more source

New Hydrazone Derivatives Featuring Isatin and Piperazine Moieties: Synthesis, Cytotoxicity Evaluation, and Molecular Modeling Studies

Journal of Applied Toxicology, EarlyView.
ABSTRACT In this study, ten novel compounds (IPH1–IPH10) were designed by integrating three pharmacophores (isatin, piperazine, and hydrazone) commonly found in the molecular structures of anticancer agents. The target molecules were obtained by the reaction of in‐house prepared 4‐(4‐(pyridin/pyrimidin‐2‐yl)piperazin‐1‐yl)benzohydrazide with various ...
Semiha Köprü, Münevver Baran, Miyase Gözde Gündüz, Şengül Dilem Doğan   +3 more
wiley   +1 more source

miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cells [PDF]

, 2016
Oxaliplatin resistance in colorectal cancers (CRC) is a major medical problem, and predictive markers are urgently needed. Recently, miR-625-3p was reported as a promising predictive marker.
Primdal-Bengtson, Bjarke, Tarpgaard, Line Schmidt, Hansen, Tine Plato, Andersen, Claus Lindbjerg, Hansen, Flemming, Pfeiffer, Per, Nielsen, Morten Muhlig, Rasmussen, Mads Heilskov, Lyskjær, Iben, Pedersen, Jakob Skou, Olsen, Jesper Velgaard, Ørntoft, Torben Falck, Jersie-Christensen, Rosa Rakownikow, Pfeiffer, Per; id_orcid   +13 more
core   +1 more source

Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer

Molecular Cancer, 2019
Background Oxaliplatin resistance is a major challenge for treatment of advanced colorectal cancer (CRC). Both acquisition of epithelial-mesenchymal transition (EMT) and suppressed drug accumulation in cancer cells contributes to development of ...
Tong Liu, Xin Zhang, Lutao Du, Yunshan Wang, Xiaoming Liu, Hui Tian, Lili Wang, Peilong Li, Yinghui Zhao, Weili Duan, Yujiao Xie, Zhaowei Sun, Chuanxin Wang   +12 more
doaj   +1 more source